Research and Publications

UCL-TB spans almost every department of the School of Life and Medical Sciences at UCL, with research across basic science, microbiology, translational medicine, epidemiology and beyond with our work achieving great impact locally, nationally and globally

These are some examples of our research currently taking place.



This project will contribute to the eventual elimination of tuberculosis in the European Union by utilising evidence-based interventions to ensure early diagnosis, improve integrated care and support community and prison outreach activities in low- and high-incidence countries.


Find & Treat

This team comprises outreach specialists that work alongside over 200 NHS and third sector front-line services to tackle TB among homeless people, drug or alcohol users, vulnerable migrants and people who have been in prison.



(The Pan African Consortium for the Evaluation of Antituberculosis Antibiotics) is a consortium that brings together scientists from 14 countries to shorten and simplify treatment for TB. The UCL Team includes Professor TimMcHugh, Dr Patrick Phillips and Ms Sunita Rehal.



is a project investigating the genomic sequencing of 8 pathogens, including M. tb, directly from clinical samples. Researchers in the Department of Infection and Immunityhave successfully developed a system where full genomes of M.tb can be sequenced directly from clinical samples, without the need to culture.



The Innovative Medicines Intiative (IMI) has funded the PreDiCT-TB consortium to determine and validate improved methods for pre-clinical drug discovery and development. This will be achieved by integrating multiple in vitro and in vivo models to predict the efficacy of different drug combinations against TB in an aim to identify an optimized decision pathway for the best combination regimens to progress into clinical trials.


Shaking up TB diagnostics with nanotechnology

Nanotechnology provides an exiting opportunity in the world of diagnostics. Current methods for diagnosing TB and detecting resistant strains of TB are hampered by cost, speed or sensitivity. This team is using nanotechnology to create a diagnostic tool which will provide an antibiogram in a matter of minutes.



The STAND trial tests the first regimen designed to significantly shorten and simplify the treatment of drug-sensitive and drug-resistant TB and is a joint project carried out in conjunction with UCL and the TB Alliance.



This project is investigating a standardised treatment regimen of drugs to treat patients with Multi-drug Resistant Tuberculosis (MDR-TB). The aim of this investigation is to show that a shorter, 9-month treatment is at least as effective as the current regimen used throughout the world.



The UK PREDICT Study will assess the efficacy of the two current TB (tuberculosis) blood tests (Interferon Gamma Release Assays (IGRA)) compared with the standard skin test (Mantoux Tuberculin Skin Test (TST)), for predicting active tuberculosis among those at increased risk of TB.